Bedotto J B, Gay R G, Graham S D, Morkin E, Goldman S
Department of Internal Medicine, Veterans Administration Medical Center, Tucson, Arizona.
J Pharmacol Exp Ther. 1989 Feb;248(2):632-6.
This study was designed to determine whether thyroid hormone (T4) produces cardiac hypertrophy and alters ventricular function by direct effects on the heart or by alterations in adrenergic stimulation or changes in the peripheral circulation. Rats were treated with captopril (4 mg/ml of drinking water), propranolol (0.5 mg/ml of drinking water), hydralazine (80 mg/l of drinking water) or the combination of captopril and propranolol with and without T4 (15 micrograms/100 g b.w. i.p.). After 10 days, T4 increased (P less than .01) heart rate, left ventricular (LV) dP/dt and LV weight/body weight, but did not alter LV systolic pressure (SP) or enddiastolic pressure (EDP). Compared to treatment with T4 alone, captopril plus T4 decreased LV SP (P less than .05) and LV EDP (P less than .01); however, heart rate, LV dP/dt and LV weight/body weight were unchanged. Treatment with T4 plus propranolol decreased heart rate and LV EDP (P less than .05) compared to T4 alone; however, LV SP, LV dP/dt and LV weight/body weight were unchanged (P greater than .05). Hydralazine did not alter (P greater than .05) heart rate, LV SP, LV EDP or prevent the development of increased LV weight/body weight when given with T4; however, LV dP/dt was slightly decreased (P less than .05). Treatment with the combination of captopril and propranolol did not alter (P greater than .05) heart rate, LV SP, LV EDP or LV dP/dt and also failed to prevent the development of increased LV weight/body weight and LV dP/dt when given with T4.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在确定甲状腺激素(T4)是否通过直接作用于心脏、改变肾上腺素能刺激或外周循环变化而导致心脏肥大并改变心室功能。给大鼠饮用含卡托普利(4毫克/毫升)、普萘洛尔(0.5毫克/毫升)、肼屈嗪(80毫克/升)的水,或饮用含卡托普利与普萘洛尔组合的水,同时给予或不给予T4(15微克/100克体重,腹腔注射)。10天后,T4增加了(P<0.01)心率、左心室(LV)dP/dt和LV重量/体重,但未改变LV收缩压(SP)或舒张末期压力(EDP)。与单独使用T4治疗相比,卡托普利加T4降低了LV SP(P<0.05)和LV EDP(P<0.01);然而,心率、LV dP/dt和LV重量/体重未改变。与单独使用T4相比,T4加普萘洛尔治疗降低了心率和LV EDP(P<0.05);然而,LV SP、LV dP/dt和LV重量/体重未改变(P>0.05)。肼屈嗪与T4合用时,未改变(P>0.05)心率、LV SP、LV EDP,也未阻止LV重量/体重增加的发展;然而,LV dP/dt略有降低(P<0.05)。卡托普利和普萘洛尔联合治疗未改变(P>0.05)心率、LV SP、LV EDP或LV dP/dt,与T4合用时也未能阻止LV重量/体重和LV dP/dt增加的发展。(摘要截断于250字)